Developer docs
API playgroundTry for free, no card

Search company profiles

HighLife

Full company profile

uuid00021bq

Namestring
HighLife
Legal namestring
HighLife SAS
Company typeenum
Private
Founded yearint
2010
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transcatheter mitral valve replacement, structural heart devices, mitral regurgitation therapy, cardiac valve implants, transseptal heart valve systems
Industry2 codes
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Transcatheter Mitral Valve Replacement Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1TMVR Device Sales
TypeHardware Sales
Description

Pre-commercial company with CE Mark approval received January 2026. Revenue expected from sale of TSMVR devices to hospitals and cardiac centers in Europe, with future expansion to US and other markets following regulatory approvals.

highlifemedical.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

HighLife develops and manufactures the HighLife TSMVR (Trans-Septal Mitral Valve Replacement) System, a transcatheter device for treating symptomatic moderate-to-severe mitral regurgitation in patients unsuitable for surgery or transcatheter edge-to-edge repair. The product is a dual-component valve-in-ring implant delivered transfemorally via a trans-septal approach and is sold to hospitals and cardiac centers, with CE Mark approval secured in January 2026 enabling European commercial launch.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 90% technical success rate in clinical data
+5 more records
Product overview1 text field

HighLife Medical is a pre-commercial stage MedTech company developing the HighLife TSMVR (Trans-Septal Mitral Valve Replacement) system - a novel transcatheter solution for treating moderate to severe mitral regurgitation. The system consists of a dual-component valve-in-ring design: a bovine pericardial valve that self-centers within a sub-annular ring implanted percutaneously via transfemoral transseptal approach. The product portfolio includes Standard and Clarity valve variants, with the Clarity variant designed for patients at risk of left ventricular outflow tract obstruction. The company recently received CE Mark approval (January 2026) for commercial introduction in Europe and continues US pivotal clinical trials. The system addresses patients who are unsuitable for surgery or transcatheter edge-to-edge repair (TEER).

Product and service1 record
1HighLife TSMVR (Trans-Septal Mitral Valve Replacement) System
CategoryTranscatheter Heart Valve Replacement Device
Description

A transcatheter mitral valve replacement system using a dual-component valve-in-ring design (bovine pericardial valve plus sub-annular ring) delivered transfemorally via a trans-septal approach. Indicated for adult patients with symptomatic moderate-severe or severe mitral regurgitation who are unsuitable for surgical repair/replacement or transcatheter edge-to-edge repair (TEER). Available in Standard and Clarity configurations (with the Clarity variant for patients at risk of LVOTO) and in Large Annulus Valve sizes accommodating annuli up to 53 mm. Sold to hospitals and structural heart centers.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-12-21
Description

License and technology transfer agreement for trans-septal mitral valve replacement in Greater China. HighLife granted Peijia exclusive license for manufacturing, development, and commercialization in the greater China region. Peijia pays upfront fee and milestone payments. A joint review committee oversees development and commercialization. The partnership enabled first clinical use of HighLife technology in China within 12 months of agreement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major structural heart medtech incumbent with PASCAL and SAPIEN M3 transcatheter mitral programs. Comparable to HighLife as both target transcatheter mitral regurgitation treatment, though Edwards operates across the broader structural heart portfolio including TAVR leadership.

TypeBroad incumbent
Description

Global medtech leader developing Intrepid TMVR system for mitral regurgitation. Comparable as a direct TMVR competitor with deeper resources, established structural heart sales force, and extensive clinical evidence program. Acquired CoreValve (HighLife founder's previous company) for $700M+.

3Abbott
TypeBroad incumbent
Description

Structural heart incumbent with Tendyne transcatheter mitral valve (acquired 2015) and MitraClip market leadership. Directly competes in the mitral regurgitation treatment space with significant commercial infrastructure and physician relationships.

4Venus MedTech
TypeEmerging player
Description

Chinese structural heart company developing Cardiovalve transcatheter mitral valve replacement system. Comparable as emerging TMVR player with CE Mark approval and progress toward global commercialization, including potential APAC market overlap with HighLife.

TypeEmerging player
Description

Early-stage medical device company developing AltaValve transcatheter mitral valve replacement technology. Directly comparable as emerging TMVR competitor with novel approach to mitral regurgitation treatment in clinical trials.

TypeEmerging player
Description

TMVR developer acquired by Abbott in 2019 for $300M+ upfront. Provides a comparable exit reference for HighLife as both focused on transcatheter mitral valve replacement technology, though Cephea was acquired pre-commercialization.

7Neovasc
TypeEmerging player
Description

Developer of Tiara transcatheter mitral valve replacement, acquired by Edwards Lifesciences. Comparable as TMVR technology that was acquired by a major incumbent, providing another recent exit reference for HighLife's technology category.

TypeEmerging player
Description

Early-stage medtech developing transcatheter tricuspid and mitral valve technologies. Comparable as emerging structural heart company developing transcatheter valve replacement solutions with similar clinical and regulatory pathway.

TypeEmerging player
Description

Norwegian medical device company developing transcatheter mitral valve repair technology. Comparable as European-based emerging structural heart company with similar regulatory pathway and target patient population.

TypeOthers
Description

Chinese structural heart company that is both a strategic partner (Greater China licensee for HighLife) and adjacent peer developing its own transcatheter valve technologies including TaurusTrio for mitral regurgitation. Provides both partnership and competitive context for HighLife.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HighLife

Transcatheter Mitral Valve Replacement Deviceshighlifemedical.com

HighLife firmographics

Firmographics
Name
HighLife
Legal name
HighLife SAS
Website
https://highlifemedical.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

HighLife industry classification

Industry
Product category
Transcatheter Mitral Valve Replacement Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Transcatheter mitral valve replacement
  • Structural heart devices
  • Mitral regurgitation therapy
  • Cardiac valve implants
  • Transseptal heart valve systems

Where HighLife is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices2 records

Markets served

HighLife business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. TMVR Device Sales: Pre-commercial company with CE Mark approval received January 2026. Revenue expected from sale of TSMVR devices to hospitals and cardiac centers in Europe, with future expansion to US and other markets following regulatory approvals.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

HighLife product offering

Product offering

Core offering

HighLife develops and manufactures the HighLife TSMVR (Trans-Septal Mitral Valve Replacement) System, a transcatheter device for treating symptomatic moderate-to-severe mitral regurgitation in patients unsuitable for surgery or transcatheter edge-to-edge repair. The product is a dual-component valve-in-ring implant delivered transfemorally via a trans-septal approach and is sold to hospitals and cardiac centers, with CE Mark approval secured in January 2026 enabling European commercial launch.

Product overview

HighLife Medical is a pre-commercial stage MedTech company developing the HighLife TSMVR (Trans-Septal Mitral Valve Replacement) system - a novel transcatheter solution for treating moderate to severe mitral regurgitation. The system consists of a dual-component valve-in-ring design: a bovine pericardial valve that self-centers within a sub-annular ring implanted percutaneously via transfemoral transseptal approach. The product portfolio includes Standard and Clarity valve variants, with the Clarity variant designed for patients at risk of left ventricular outflow tract obstruction. The company recently received CE Mark approval (January 2026) for commercial introduction in Europe and continues US pivotal clinical trials. The system addresses patients who are unsuitable for surgery or transcatheter edge-to-edge repair (TEER).

Differentiator

Problem solved

Functional benefit

Products and services

  • HighLife TSMVR (Trans-Septal Mitral Valve Replacement) System A transcatheter mitral valve replacement system using a dual-component valve-in-ring design (bovine pericardial valve plus sub-annular ring) delivered transfemorally via a trans-septal approach. Indicated for adult patients with symptomatic moderate-severe or severe mitral regurgitation who are unsuitable for surgical repair/replacement or transcatheter edge-to-edge repair (TEER). Available in Standard and Clarity configurations (with the Clarity variant for patients at risk of LVOTO) and in Large Annulus Valve sizes accommodating annuli up to 53 mm. Sold to hospitals and structural heart centers.

Quantifiable outcome

  • 90% technical success rate in clinical data
  • +5 more outcomes

Companies that use HighLife

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles1 record

HighLife technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

HighLife partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Peijia MedicalcoreOEM/ Whitelabel/ Licensing Partner · 21 December 2020License and technology transfer agreement for trans-septal mitral valve replacement in Greater China. HighLife granted Peijia exclusive license for manufacturing, development, and commercialization in the greater China region. Peijia pays upfront fee and milestone payments. A joint review committee oversees development and commercialization. The partnership enabled first clinical use of HighLife technology in China within 12 months of agreement.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

HighLife competitors and assessment

Company assessment

Broad incumbents

  • Edwards Lifesciences: Major structural heart medtech incumbent with PASCAL and SAPIEN M3 transcatheter mitral programs. Comparable to HighLife as both target transcatheter mitral regurgitation treatment, though Edwards operates across the broader structural heart portfolio including TAVR leadership.
  • Medtronic: Global medtech leader developing Intrepid TMVR system for mitral regurgitation. Comparable as a direct TMVR competitor with deeper resources, established structural heart sales force, and extensive clinical evidence program. Acquired CoreValve (HighLife founder's previous company) for $700M+.
  • Abbott: Structural heart incumbent with Tendyne transcatheter mitral valve (acquired 2015) and MitraClip market leadership. Directly competes in the mitral regurgitation treatment space with significant commercial infrastructure and physician relationships.

Emerging players

  • Venus MedTech: Chinese structural heart company developing Cardiovalve transcatheter mitral valve replacement system. Comparable as emerging TMVR player with CE Mark approval and progress toward global commercialization, including potential APAC market overlap with HighLife.
  • 4C Medical Technologies: Early-stage medical device company developing AltaValve transcatheter mitral valve replacement technology. Directly comparable as emerging TMVR competitor with novel approach to mitral regurgitation treatment in clinical trials.
  • Cephea Valve Technologies: TMVR developer acquired by Abbott in 2019 for $300M+ upfront. Provides a comparable exit reference for HighLife as both focused on transcatheter mitral valve replacement technology, though Cephea was acquired pre-commercialization.
  • Neovasc: Developer of Tiara transcatheter mitral valve replacement, acquired by Edwards Lifesciences. Comparable as TMVR technology that was acquired by a major incumbent, providing another recent exit reference for HighLife's technology category.
  • CroiValve: Early-stage medtech developing transcatheter tricuspid and mitral valve technologies. Comparable as emerging structural heart company developing transcatheter valve replacement solutions with similar clinical and regulatory pathway.
  • CardioMech: Norwegian medical device company developing transcatheter mitral valve repair technology. Comparable as European-based emerging structural heart company with similar regulatory pathway and target patient population.

Others

  • Peijia Medical: Chinese structural heart company that is both a strategic partner (Greater China licensee for HighLife) and adjacent peer developing its own transcatheter valve technologies including TaurusTrio for mitral regurgitation. Provides both partnership and competitive context for HighLife.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

HighLife social profiles

Digital presence

HighLife compliance and trust

Trust signal

Compliance3 records

HighLife financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HighLife leadership team

Management profile

Number of profiles

Profiles1 record

HighLife subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

HighLife funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HighLife M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HighLife

What does HighLife do?

HighLife develops and manufactures the HighLife TSMVR (Trans-Septal Mitral Valve Replacement) System, a transcatheter device for treating symptomatic moderate-to-severe mitral regurgitation in patients unsuitable for surgery or transcatheter edge-to-edge repair. The product is a dual-component valve-in-ring implant delivered transfemorally via a trans-septal approach and is sold to hospitals and cardiac centers, with CE Mark approval secured in January 2026 enabling European commercial launch.

Is HighLife a public or private company?

HighLife is a private company. It is classified as venture growth investor backed and is currently operating.

When was HighLife founded?

HighLife was founded in 2010. It employs 51 to 100 people.

Where is HighLife based?

HighLife is headquartered in Paris, France, in the Europe region.

How does HighLife make money?

One revenue line is on record: TMVR Device Sales.

Who are HighLife's main competitors?

Broad incumbents on record are Edwards Lifesciences, Medtronic and Abbott. Emerging players are Venus MedTech, 4C Medical Technologies, Cephea Valve Technologies, Neovasc, CroiValve and CardioMech. Peijia Medical is listed as an others.

Does HighLife have an API?

No public API is recorded for HighLife.

What industry is HighLife in?

HighLife's product category is Transcatheter Mitral Valve Replacement Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FRENCHWEB.FRHighLife, Biolevate, Wealthcome : près de 189 millions d’euros levés dans la French Tech cette semaineFourteen French tech companies raised nearly 189 million euros in one week, with HighLife and Biolevate leading at over 110 million euros combined. The health sector attracted the largest amounts, while business software and AI infrastructure rounds were tied to critical workflows. The data shows capital flows to companies needing regulatory or industrial proof.Pulse 2.0HighLife Medical Raises More Than $90 Million To Advance U.S. Clinical Study And European ExpansionHighLife Medical raised over $90 million in financing to advance its U.S. clinical study and accelerate European commercial expansion. The funds will support its Transcatheter Mitral Valve Replacement system, which received CE Mark approval in January and July 2026. The company plans to use the capital for European expansion and strengthening its organization.TechStartupsStartup Funding News Today, September 22, 2026: Benford, CellPoint, HighLife, BCI-Sonics, Spott & MoreOn September 22, 2026, multiple startups raised over $133 million in AI-related funding, including HighLife's $90 million for a mitral-valve device and CellPoint's $34 million for travel payments. The deals reflect AI moving into regulated and operational workflows, with human oversight built into products like Spott and Benford.VentureburnHighLife Raises $90 Million To Start US Heart Valve Study and Grow in EuropeHighLife raised over $90 million in a financing round led by Andera Partners, Sofinnova Partners, Supernova Invest, and Mérieux Equity Partners. The funds will support its US pivotal study for mitral valve replacement and expand sales in Europe, following CE Mark approvals for its TMVR system and Clarity Valve.MaddynessCardiologie: HighLife lève près de 80 millions d'eurosHighLife, a French startup developing a catheter-based mitral valve replacement, raised over $90 million. The funds will accelerate European commercialization and support US clinical development. The company also obtained CE marking for its system in January and for its new valve in July.The future of tradingHighLife raises EUR 80 million in funding round backed by VI PartnersHighLife raised over USD 90 million (EUR 80 million) in a private financing round to fund a US pivotal study. Proceeds also target faster European commercial expansion after CE Mark clearance for its transcatheter mitral valve replacement system. The round was co-led by Andera Partners, Sofinnova Partners, Supernova Invest, and Mérieux Equity Partners, with VI Partners as an existing investor.The future of tradingCapricorn Partners joins HighLife’s €80 million financing round to fund TMVR rolloutHighLife closed a $90+ million (€80 million) private financing round with Capricorn Partners joining as a new investor. Proceeds will fund a US pivotal study, accelerate European commercial expansion, and support long-term growth. The company also secured CE Mark clearance for its TMVR system and next-generation Clarity Valve.The future of tradingHighLife raises €80 million in funding round co-led by Sofinnova Partners, Andera PartnersHighLife raised over €80 million in a private financing round co-led by Sofinnova Partners. The Paris-based MedTech developer will use proceeds to start a US pivotal study, scale commercial rollout in Europe, and strengthen its organization. The company recently secured a CE mark for its TMVR system and a second-generation Clarity valve.ANDERA PARTNERSHighlife, in our Andera Life Sciences portfolio company, Raises $90+ Million to start its US Pivotal Study and accelerate Commercial Expansion in Europe. - ANDERA PARTNERSHighLife SAS raised over $90 million in a financing round co-led by Andera Partners and others. The capital will fund its US pivotal clinical study and European commercial expansion. The company also received CE Mark approvals for its TMVR system and Clarity Valve this year.Biotech FinancesHIGHLIFE: $90M FOR A VALIANT HEARTHighLife, a Parisian medtech firm, closed a round exceeding $90 million co-led by four funds with new investors and a strategic player. The funding will fund two to three years of operations and support U.S. expansion. CEO Stefan Pilz said the company is not targeting an acquisition but long-term growth.